^
Association details:
| Biomarker: | NRAS Q61 |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Excerpt:
Vectibix is not indicated for the treatment of patients with colorectal cancer that harbor somatic RAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of either KRAS or NRAS…
Source:
Title:
A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
Published date:
11/08/2016
Excerpt:
Patients with wild-type KRAS exon 2 tumours but with other RAS mutations did not benefit from panitumumab therapy. In this group, the HRs (95% CI) for OS and PFS for panitumumab plus BSC vs BSC alone were 0.99 (0.49–2.00; Supplementary Figure 2A) and 1.03 (0.56–1.90; Supplementary Figure 2B), respectively.
DOI:
10.1038/bjc.2016.309
Trial ID:
